Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on March 13, 2023. The registrant is a Delaware corporation with its principal executive offices in Boston, Massachusetts, and its common stock trades on The Nasdaq Stock Market under the symbol NRBO.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report is limited to a specific disclosure regarding the company's banking relationships.
Material Changes
There are no material changes to financial performance or operations reported in this document. The sole material disclosure addresses the company's exposure to the Silicon Valley Bank (SVB) situation.
Management Commentary and Risks
Under Item 7.01 (Regulation FD Disclosure), management explicitly states that NeuroBo Pharmaceuticals, Inc. does not hold cash deposits or securities at Silicon Valley Bank. This disclosure was made to inform investors and stockholders regarding the company's liquidity position in the context of the SVB closure. The filing notes that this information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the registrant name is NeuroBo Pharmaceuticals, Inc. (NRBO), not Metavia Inc.
- Confirm the company has no direct exposure to Silicon Valley Bank deposits or securities as of March 13, 2023.
- Note that this filing contains no financial performance data; refer to the latest 10-K or 10-Q for revenue and cash flow details.